Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-World EFFECT Study (P1.362)
Sign Up to like & getrecommendations! Published in 2018 at "Neurology"
DOI: 10.26226/morressier.59a3e8b6d462b8028d8951f5
Abstract: Objective: To compare real-world effectiveness of delayed-release dimethyl fumarate (DMF) with fingolimod (FTY) in relapsing-remitting multiple sclerosis (RRMS) patients. Background: In real-world comparative effectiveness studies of RRMS patients, including claims data and registries, treatment with… read more here.
Keywords: stock options; dmf fty; stock stock; stock ... See more keywords